nach oben

Breast Cancer Research

Erschienen in:

01.04.2006 | Review

Overdiagnosis and overtreatment of breast cancer: Progression of ductal carcinoma in situ: the pathological perspective

verfasst von: J Louise Jones

Erschienen in: Breast Cancer Research | Ausgabe 2/2006

Einloggen, um Zugang zu erhalten

Abstract

Ductal carcinoma in situ (DCIS) is encountered much more frequently in the screening population compared to the symptomatic setting. The behaviour of DCIS is highly variable and this presents difficulties in choosing appropriate treatment strategies for individual cases. This review discusses the current data on the frequency and rate of progression of DCIS, the value and limitations of clinicopathological and biological variables in predicting disease behaviour and suggests strategies to develop more robust means of predicting progression of DCIS.

Ernster VL, Barclay J, Kerlikowske K, Wilkie H, Ballard-Barbash R: Mortality among women with ductal carcinoma in situ of the breast in the population-based surveillance, epidemiology and end results program. Arch Intern Med. 2000, 160: 953-958. 10.1001/archinte.160.7.953.CrossRefPubMed

Van Dongen JA, Fentiman IS, Harris JR, Holland R, Peterse JL, Salvadori B, Stewart HJ: In situ breast cancer: the EORTC consensus meeting. Lancet. 1989, ii: 25-27. 10.1016/S0140-6736(89)90263-8.CrossRef

Schnitt SJ: Flat epithelial atypia – classification, pathologic features and clinical significance. Breast Cancer Res. 2003, 5: 263-268. 10.1186/bcr625.CrossRefPubMedPubMedCentral

Saunders ME, Schuyler PA, Dupont WD, Page DL: The natural history of low grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer. 2005, 103: 2481-2484. 10.1002/cncr.21069.CrossRef

Collins LC, Tamimi RM, Baer HJ, Connoly JL, Colditz GA, Schnitt SJ: Outcome of patients with ductal carcinoma in situ untreated after diagnostic biopsy. Results from the Nurses' Health Study. Cancer. 2005, 103: 1778-1784. 10.1002/cncr.20979.CrossRefPubMed

Van Dongen JA, Holland R, Peterse JL, Fentiman IS, Lagios MD, Millis RR, Recht A: Ductal carcinoma in situ of the breast: second EORTC consensus meeting. Eur J Cancer. 1992, 28: 626-629. 10.1016/S0959-8049(05)80113-3.CrossRefPubMed

Silverstein MJ, Lagios MD, Craig PH, Waisman JR, Lewinsky BS, Colburn WJ, Poller DN: A prognostic index for ductal carcinoma in situ of the breast. Cancer. 1996, 77: 2267-2274. 10.1002/(SICI)1097-0142(19960601)77:11<2267::AID-CNCR13>3.0.CO;2-V.CrossRefPubMed

National Coordinating Group for Breast Screening Pathology: Guidelines for Pathology Reporting in Breast Cancer Screening. 2005, Sheffield: NHSBSP Publications, 3

Badve S, A'Hern RP, Ward AM, Millis RR, Pinder SE, Ellis IO, Gusterson BA, Sloane JP: Prediction of local recurrence of ductal carcinoma in situ of the breast using five histological classifications: a comparative study with long follow-up. Hum Pathol. 1998, 29: 915-923. 10.1016/S0046-8177(98)90196-4.CrossRefPubMed

10.

Skinner KA, Silverstein MJ: The management of ductalcarcinoma in situ of the breast. Endocr Relat Cancer. 2001, 8: 33-45. 10.1677/erc.0.0080033.CrossRefPubMed

11.

Bijker N, Peterse JL, Julien J-P, Fentimen IS, Duval C, Di Palma S, Simony-Lafontaine J, de Mascarel I, van de Vijver M: Risk factors for recurrence and metastasis after breast conserving therapy for ductal carcinoma in-situ: analysis of European organisation for research and treatment of cancer trial 10853. J Clin Oncol. 2001, 19: 2263-2271.PubMed

12.

Silverstein MJ, Lagios MD, Groshen S, Waisman JR, Lewinsky BS, Martino S, Gamagami P, Colburn WJ: The influence of margin width on local control of ductal carcinoma in situ of the breast. N Eng J Med. 1999, 340: 1455-1461. 10.1056/NEJM199905133401902.CrossRef

13.

Millis RR, Ryder K, Fentiman IS: Ductal carcinoma in situ and prognosis in invasive mammary carcinoma. Breast Cancer Res Treat. 2004, 84: 197-198. 10.1023/B:BREA.0000018434.04960.02.CrossRefPubMed

14.

Simpson PT, Reis-Filho JS, Gale T, Lakhani SR: Molecular evolution of breast cancer. J Pathol. 2005, 205: 248-254. 10.1002/path.1691.CrossRefPubMed

15.

Betsill WLJ, Rosen PP, Lieberman PH, Robbins GF: Intraductal carcinoma. Long tern follow-up after treatment by biopsy alone. J Am Med Assoc. 1978, 239: 1863-1867. 10.1001/jama.239.18.1863.CrossRef

16.

Eusebi V, Feudale E, Foschini MP, Micheli A, Conti A, Riva C, Di Palma S, Rilke F: Long-term follow-up of in-situ carcinoma of the breast. Semin Diagn Pathol. 1994, 11: 223-235.PubMed

17.

Cornfield DB, Palazzo JP, Schwartz GF, Goonewardene SA, Kovatich AJ, Chervoneva I, Hyslop T, Schwarting R: The prognostic significance of multiple morphologic features and biologic markers in ductal carcinoma in situ of the breast. A study of a large cohort of patients treated with surgery alone. Cancer. 2004, 100: 2317-2327. 10.1002/cncr.20260.CrossRefPubMed

18.

Ringberg A, Anagnostaki L, Anderson H, Idvall I, Ferno M: Cell biological factors in ductal carcinoma in situ (DCIS) of the breast – relationship to ipsilateral local recurrence and histopathological characteristics. Eur J Cancer. 2001, 37: 1514-1522. 10.1016/S0959-8049(01)00165-4.CrossRefPubMed

19.

Done SJ, Eskandarain S, Bull S, Redson M, Andrulis IL: p53 mis-sense mutation in microdissected high grade ductal carcinoma insitu of the breast. J Natl Cancer Inst. 2001, 93: 700-704. 10.1093/jnci/93.9.700.CrossRefPubMed

20.

Barnes NLP, Khavari S, Boland GP, Cramer A, Knox WF, Bundred NJ: Absence of HER4 expression predicts recurrence of ductal carcinoma in situ of the breast. Clin Cancer Res. 2005, 11: 2163-2168. 10.1158/1078-0432.CCR-04-1633.CrossRefPubMed

21.

Sartor CI, Zhou H, Kozlowska E, Guttridge K, Kawata E, Caskey L, Harrelson J, Hynes N, Ethier S, Calvo B, Earp HS: HER4 mediates ligand dependent antiproliferative and differentiation responses in human breast cancer cells. Mol Cell Biol. 2001, 21: 4265-4275. 10.1128/MCB.21.13.4265-4275.2001.CrossRefPubMedPubMedCentral

22.

Ma XJ, Salunga R, Tuggle JT, Gaudet J, Enright E, McQuary P, Payette T, Pistone M, Stecker K, Zhang BM, et al: Gene expression profiles of breast cancer progression. Proc Natl Acad Sci USA. 2003, 100: 5974-5979. 10.1073/pnas.0931261100.CrossRefPubMedPubMedCentral

23.

Weigelt B, Wessels LFA, Bosma AJ, Glas AM, Nuyten DSA, He YD, Dai H, Peterse JL, van't Veer LJ: No common denominator for breast cancer lymph node metastasis. Br J Cancer. 2005, 93: 924-932. 10.1038/sj.bjc.6602794.CrossRefPubMedPubMedCentral

24.

Tot T: DCIS, cytokeratins and the theory of the sick lobe. Virchows Arch. 2005, 447: 1-8. 10.1007/s00428-005-1274-7.CrossRefPubMed

25.

Adams M, Jones JL, Walker RA, Pringle JH, Bell SC: Altered Tenascin-C isoform expression in invasive and pre-invasive breast cancer. Cancer Res. 2002, 62: 3289-3297.PubMed

26.

Allinen M, Beroukhim R, Cal LI, Brennan C, Lahti-Domenici J, Huang H, Porter D, Hu M, Chin L, Richardson A, et al: Molecular characterisation of tumour microenvironment in breast cancer. Cancer Cell. 2004, 6: 17-32. 10.1016/j.ccr.2004.06.010.CrossRefPubMed

27.

Nielsen BS, Rank F, Lopez JM, Balbin M, Vizoso F, Lund LR, Dano K, Lopez-Otin C: Collagenase-3 expression in breast myofi-broblasts as a molecular marker of transition of ductal carcinoma in-situ lesions to invasive ductal carcinomas. Cancer Res. 2001, 61: 7091-7100.PubMed

Titel: Overdiagnosis and overtreatment of breast cancer: Progression of ductal carcinoma in situ: the pathological perspective
verfasst von: J Louise Jones
Publikationsdatum: 01.04.2006
Verlag: BioMed Central
Erschienen in: Breast Cancer Research / Ausgabe 2/2006
Elektronische ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr1397

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Overdiagnosis and overtreatment of breast cancer: Progression of ductal carcinoma in situ: the pathological perspective

Abstract

Neu im Fachgebiet Onkologie

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Update Onkologie

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2006

Germline polymorphisms in SIPA1are associated with metastasis and other indicators of poor prognosis in breast cancer

Erratum to: Increased copy number at 3p14 in breast cancer

Effect of a farnesyl transferase inhibitor (R115777) on ductal carcinoma in situ of the breast in a human xenograft model and on breast and ovarian cancer cell growth in vitro and in vivo

Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort

Is there a positive association between mammographic density and bone mineral density? Authors' response

Growth of a human mammary tumor cell line is blocked by galangin, a naturally occurring bioflavonoid, and is accompanied by down-regulation of cyclins D3, E, and A

Neu im Fachgebiet Onkologie

Bei seelischem Stress sind Checkpoint-Hemmer weniger wirksam

Antikörper mobilisiert Neutrophile gegen Krebs

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

15% bedauern gewählte Blasenkrebs-Therapie

Update Onkologie